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NPC1Cholesterol accumulation in Niemann–Pick type C disease (NPC) causes increased levels of the amyloid-
precursor-protein C-terminal fragments (APP-CTFs) and intracellular amyloid-β peptide (Aβ), the two
central molecules in Alzheimer's disease (AD) pathogenesis. We previously reported that cholesterol accu-
mulation in NPC-cells leads to cholesterol-dependent increased APP processing by β-secretase (BACE1) and
decreased APP expression at the cell surface (Malnar et al. Biochim Biophys Acta. 1802 (2010) 682–691.).
We hypothesized that increased formation of APP-CTFs and Aβ in NPC disease is due to cholesterol-
mediated altered endocytic trafﬁcking of APP and/or BACE1. Here, we show that APP endocytosis is prereq-
uisite for enhanced Aβ levels in NPC-cells. Moreover, we observed that NPC cells show cholesterol depen-
dent sequestration and colocalization of APP and BACE1 within enlarged early/recycling endosomes which
can lead to increased β-secretase processing of APP. We demonstrated that increased endocytic localization
of APP in NPC-cells is likely due to both its increased internalization and its decreased recycling to the cell
surface. Our ﬁndings suggest that increased cholesterol levels, such as in NPC disease and sporadic AD, may
be the upstream effector that drives amyloidogenic APP processing characteristic for Alzheimer's disease by
altering endocytic trafﬁcking of APP and BACE1.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
A key event in Alzheimer's disease (AD) pathogenesis is the pro-
teolytic processing of the β-amyloid precursor protein (APP) by the
two proteases, β- and γ-secretase leading to the formation of the
amyloid-β (Aβ) peptide which accumulates in AD brains [1]. β-
Secretase (BACE1) cleavage of APP generates two products [2]: the
N-terminal secreted APPβ fragment (sAPPβ) and the C-terminal
membrane bound fragment (CTFβ/C99) that is further cleaved by
γ-secretase complex (composed of presenilin 1/2 — PS1/2, nicastrin,
Aph1 and Pen2) to generate Aβ peptides [3–6]. In parallel with amy-
loidogenic β-secretase pathway, APP can also be processed through
the non-amyloidogenic α-secretase pathway, which precludes the
generation of Aβ. β-Secretase cleavage of APPwt is thought to happen
primarily within endosomal compartments [7–9] and cleavage of APP
by α-secretase has been suggested to occur mainly at the cell surface
[10]. A modulation of these pathways represents a rational thera?
A3B2 show $132#$132#?>peutic approach to control Aβ formation
[11]. Recent evidence increasingly implicates intracellular APP
trafﬁcking as a main mechanism regulating the access of APP to itsc).
l rights reserved.secretases and thus Aβ generation [12]. Moreover, endosome abnor-
malities and altered endocytic APP trafﬁcking was reported to be in-
volved in early steps of the disease pathogenesis [13–15] and
upregulation of endocytosis leads to increased formation of Aβ
[16,17]. Additionally, it has been recently shown that increased cho-
lesterol levels initiate endosome enlargement and increased amyloi-
dogenic processing of APP [18], supporting that alterations in
cholesterol metabolism could initiate AD pathogenesis.
The close link between cholesterol and AD has been revealed in
an inherited lipid storage disorder (LSD) of altered cholesterol
transport, Niemann Pick Type C (NPC) disease, which is caused by
dysfunction of NPC1/2 protein leading to accumulation of free cho-
lesterol in late endosomal/lysosomal compartments. In vitro and in
vivo ﬁndings showed that accumulation of cholesterol upon NPC1
dysfunction causes a signiﬁcant increase of the APP-C-terminal frag-
ments (CTFs) and intracellular Aβ [19–23] and a shift in PS1 locali-
zation towards early/late endosomes [20,21]. Increased Aβ42 levels
were also observed in the CSF of NPC patients [24] and in the hip-
pocampus of NPC brains, while increased APP-CTFs were detected
in the NPC cerebellum [25]. Interestingly, accumulation of APP-
CTFs and Aβ has been recently identiﬁed in several other LSDs
[26,27]. Additionally, NPC1-depletion (NPC1+/−) in AD-transgenic
mouse model (PS1xAPP) enhances the progression of AD by in-
creasing Aβ accumulation [28]. More recently, altered expression
of NPC1 mRNA/protein was reported in AD brains [15,29], indicating
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disease. The NPC disease may thus present an innovative model to
study the molecular mechanism(s) of cholesterol-mediated APP-
CTF/Aβ accumulation in which a defect in a single gene involved
in cholesterol trafﬁcking (NPC1) causes AD-like phenotype.
We recently demonstrated that increased Aβ in CHO-NPC1−/−
(NPC) cells is mediated by cholesterol-dependent increased process-
ing of APP by β-secretase (BACE1) [23] probably due to decreased
expression of APP at the cell surface and its increased partitioning
into cholesterol-rich membranes — lipid rafts [30]. In this work we
further analyzed the mechanism of cholesterol-accumulation on in-
creased BACE1-cleavage of APP in NPC cells. Our results demon-
strate that accumulation of cholesterol due to NPC1 dysfunction
contributes to accumulation of Aβ by modulating endocytic trafﬁck-
ing of APP and BACE1.2. Materials and methods
2.1. Antibodies
Anti-APP antibodies: 6687 (anti-APP C-terminus), 5313 (anti-APP
N-terminus), 192wt (anti-sAPPβ) and AB15 14D6 (anti-sAPPα), to-
gether with antibody 2953 (anti-presenilin1-NTF) were generous
gifts from Dr. Christian Haass. Anti-APP 22C11 was purchased from
Chemicon and APP C-terminal antibody A8717 was obtained from
Sigma Aldrich. Antibodies against EEA1 (BD Transduction), transfer-
rin receptor (Zymed), LAMP1 (Sigma Aldrich), Rab5 and Rab7
(Santa Cruz Biotechnology), actin (Sigma Aldrich) and BACE1
(ProSci) were obtained from respective companies. Anti-BMP (bis
(monoacylglycero) phosphate, BMP) clone 6C4 was kindly provided
by Dr. Jean Gruenberg.2.2. Cell lines, primary neurons, cDNA constructs and transfection
Chinese hamster ovary wild type (CHOwt) cells and CHO-NPC1−/−
(NPC) cells (kindly provided by Dr. Daniel Ory) were maintained in
DMEM:F12medium (1:1) containing 0.5 mMNa-pyruvate supplemen-
ted with 10% FBS, 2 mM L-glutamine and antibiotic/antimycotic (all
from Sigma Aldrich).
For transient expression cells were transfected using GeneJuice
(Novagen, Merck) or Lipofectamine LTX (Invitrogen) according to
the supplier's instructions. APPwt- and APPsw-6myc-tagged con-
structs were generated using pCS2+6MT vector [31]. Construct for
APP mutant lacking entire cytoplasmic domain (myc-APPΔCT), ex-
cept a short membrane anchor (KKKR-stop), was previously de-
scribed [32] and was kindly provided by Dr. Stefan Lichtenthaler. To
monitor transfection efﬁciency between the cell lines, the cells were
transiently transfected with a secreted alkaline phosphatase (SEAP)
construct (kindly provided by Dr. Raphael Kopan) in parallel wells/
dishes. Alkaline phosphatase activity was measured in the condi-
tioned medium as described previously [33] and corrected for the
protein concentration in the cell lysate.
Cell lines stably expressing HA-SEAP-APPwt (construct kindly
provided by Dr. Stefan Lichtenthaler) or BACE1-GFP (construct kindly
provided by Dr. Christine von Arnim) were established by transfection
using GeneJuice (Novagen, Merck) or Lipofectamine LTX (Invitrogen)
and selection in themedia supplementedwith an appropriate antibiotic
according to the supplier's instructions.
Hippocampal neurons were isolated from embryonic day 18 rats
as described previously [34]. The hippocampal neurons were plated
at densities of 5000 cells/cm2 in 6 cm tissue culture dishes containing
poly-L-lysine (1 mg/ml; Sigma Aldrich)-coated glass coverslips and
Neurobasal medium supplemented with 2% B27 and 0.5 mM gluta-
mine (all from Invitrogen).2.3. Sample preparation, immunoblotting and ELISA Aβ assay
Twenty four hours after transfection medium was removed,
fresh medium was added and further incubated for 24 h. Condi-
tioned media was then collected and cell lysates were prepared
as described previously [23,31]. For immunoblotting analysis, con-
ditioned media and cell lysate aliquots were mixed with 6× sam-
ple buffer (60% glycerol, 12% SDS, 3% DTT, 1/8 v/v 0.5 M Tris pH
6.8, bromphenol blue) and heated at 70 °C for 10 min. Equivalent
amounts of protein, stratiﬁed according to SEAP activity, were
loaded onto SDS-PAGE or Tris Tricine gels. Immunoblot detec-
tion was carried out using the indicated antibodies. Proteins were
visualized using chemiluminescence on documentation system from
UVItec Cambridge.
The levels of secreted, intracellular RIPA soluble and formic acid
(FA) soluble Aβ40 were determined by ELISA Aβ40 kit (Invitrogen)
as described previously [23,31].
2.4. Endosome fractionation
Endosome fractionation was performed by previously described
protocols [17,35] with some modiﬁcations. Brieﬂy, cells were
grown in ten Ø15cm-plates, washed two times in PBS and lysed
in 2 ml of homogenization buffer (250 mM sucrose, 3 mM imidaz-
ole, 1 μM EDTA, pH 7.4) containing protease inhibitor cocktail
(Roche). The lysate was passed 10 times through a 25 gage needle
and centrifuged at 1200 g for 10 min. The post nuclear supernatant
(PNS) was adjusted to 40.6% sucrose in 3 mM imidazole (Fluka),
pH 7.4 by mixing with 62% sucrose in 3 mM imidazole pH 7.4.
Four milliliters of PNS-mixture was placed at the bottom of
an ultracentrifuge tube (14×89 mm, Beckman) and was overlaid
with 4 ml of 35%, 3 ml of 25% and 1 ml of 8% sucrose in 3 mM
imidazole, pH 7.4. After centrifugation (3 h, 4 °C, 160000 g, rotor
SW41.Ti), twelve 1 ml fractions were collected from the top of
the gradient. Fractions 1 and 2 (8% and 25% interface) were pooled
as late endosome fraction (LE), fractions 4 and 5 (25% and 35% in-
terface) were pooled as early endosome fraction (EE), and fractions
8 and 9 (35% and 40.6% interface) were pooled as heavy fraction
(HF). The levels of total cholesterol in each fraction were deter-
mined using the Amplex Red Cholesterol Assay kit (Molecular
Probes, Invitrogen).
2.5. Immunocytochemistry and confocal microscopy
CHO cells grown on coverslips were ﬁxed in 4% paraformalde-
hyde, permeabilized with 0.2% saponin and blocked in 5% goat
serum (all from Sigma Aldrich). Immunostaining was performed
with indicated primary antibodies at 4 °C over night, following 1 h
of incubation with secondary anti-rabbit-Alexa488 or anti-mouse-
Alexa594 antibody (Molecular Probes, Invitrogen). The cells were
mounted (Polyvinyl alcohol mounting medium with DABCO anti-
fading, Fluka) and were viewed by Leica inverted ﬂuorescent con-
focal microscope.
For co-localization analysis of APP and BACE1, BACE1-GFP stables
were transiently transfected with APP-RFP construct (kindly provided
by Dr. Christine von Arnim) and 48 h after transfection, ﬁxed and
mounted as described above.
Immunocytochemistry on hippocampal rat neurons was per-
formed as follows. Hippocampal neurons were ﬁxed with 4% para-
formaldehyde, quenched in 50 mM ammonium chloride and
permeabilized with 0.1% Triton X-100 for 3 min. The neurons were
blocked at room temperature for 1 h using a 2% fetal bovine serum
(Invitrogen), 2% bovine serum albumin (Sigma Aldrich), and
0.2% ﬁsh gelatin (Sigma Aldrich) dissolved in phosphate-buffered
saline. Neurons were subsequently incubated with primary anti-
bodies diluted in 10% blocking solution. The secondary antibodies
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cal images were acquired on an inverted laser scanning confocal
microscope (Zeiss Axiovert 200M) with a 63×/1.4 N.A. oil immer-
sion lens. Images were taken and analyzed with the LSM 510 con-
focal software (Zeiss).2.6. Cholesterol depletion/loading and ﬁlipin staining
To deplete cholesterol cells were incubated for 48 h in the medi-
um containing 10% lipoprotein deﬁcient serum (LPDS, Cocalico Bio-
logicals) instead of FBS (LPDS treatment) or in 10% LPDS medium
containing 4 μM lovastatin and 0.25 mM mevalonate (Sigma Aldrich)
for statin treatment. In addition, we used methyl-β-cyclodextrin
(MβC, Sigma Aldrich) to acutely or chronically deplete cholesterol.
For acute depletion we treated the cells with 10 mM MβC in 10%
LPDS media for 1 h after which the cells were kept in 10% LPDS
media for 24 h. For chronic depletion we treated the cells with
1 mM MβC in 10% LPDS media for 24 h.
To load cholesterol CHOwt cells were treated with 100 μM MβC-
cholesterol complex (Sigma Aldrich) for 4 h after 24 h incubation in
10%LPDS medium [36]. To mimic NPC phenotype CHOwt cells or
7 day old neuronal cultures were treated with 3 μg/ml or 1.5 μg/ml
U18666A (Sigma Aldrich) for 48 h, respectively [19,25].
Immunostaining and confocal microscopy were performed as de-
scribed above. Filipin (Sigma Aldrich) staining was done as described
before [37]. The cells were mounted and were viewed by ﬂuorescence
microscopy (Olympus BX51).2.7. Endocytosis of BODIPY-LacCer-BSA
Endocytosis of Bodipy-LacCer (Bodipy®-FL C5-lactosylceramide
complexed to BSA from Molecular Probes, Invitrogen) was done as
described previously in Puri et al. [38] with some modiﬁcations.
Cells grown on coverslips were washed with ice cold HMEM
(10 mM Hepes-buffered minimal essential medium, pH 7.4) and
were incubated with 5 μM BODIPY-LacCer-BSA for 30 min on ice to
label the plasma membrane. The cells were then washed with cold
HMEM and incubated in warmed HMEM at 37 °C for 30 min to induce
endocytosis. Next, the cells were rinsed with cold HMEMwithout glu-
cose and ﬂuorescent lipid present at the cell surface was then re-
moved by “back exchange” (6×10 min incubations with 5% fatty
acid free BSA in HMEM without glucose). Cells were then ﬁxed,
permeabilized and immunostained as described above. The cells
were mounted (Polyvinyl alcohol mounting medium with DABCO
antifading, Fluka) and were viewed by Leica inverted ﬂuorescent con-
focal microscope.2.8. APP uptake and recycling assay
For APP uptake assay, cells were washed in warm PBS and then in-
cubated at 37 °C with anti-APP N-terminal antibody (5313) in warm
serum-free DMEM/F12 medium for indicated time periods to allow
uptake (endocytosis). After incubation, cells were washed in ice-
cold PBS, ﬁxed, permeabilized and immunostained with EEA1 anti-
body and secondary Alexa-conjugated antibodies.
For APP recycling assay, cells were washed in warm PBS and incu-
bated at 37 °C with anti-APP N-terminal antibody (5313) in serum-
free DMEM/F12 medium for 20 min to allow endocytosis. After incu-
bation, cells were washed in warm PBS and warm fresh growthmedia
was added. Cells were then incubated for the indicated time periods
at 37 °C to allow recycling. After incubation, cells were washed in
cold PBS, ﬁxed, permeabilized and immunostained with secondary
anti-rabbit-Alexa488 antibody.3. Results
3.1. APP internalization is required for increased processing of APP
through the β-secretase pathway in NPC cells
We have recently shown that CHO-NPC1−/− (NPC) cells show
cholesterol dependent increased processing of APP by β-secretase
and decreased expression of APP at the cell surface [23]. We hypoth-
esized that cholesterol-effect on Aβ and β-CTF/sAPPβ formation in
NPC cells is dependent on APP internalization, suggesting that APP
endocytosis is prerequisite for increased processing of APP by
β-secretase in NPC cells. To test this we used APP internalization
mutant that lacks the entire cytoplasmic domain (APPΔCT) [32].
APP uptake assay conﬁrmed that APPΔCT protein is not able to be in-
ternalized compared to full-length APPwt. Indeed, we observed a pro-
found cell surface APP staining in APPΔCT-transfected cells compared
to APPwt-transfected cells (supplement, Fig. S1). We showed that
APPΔCT-transfected NPC cells like CHOwt cells exert signiﬁcantly
decreased levels of both soluble (RIPA-extractable) and aggregated
(FA-extractable) intracellular Aβ40 compared to APPwt-transfected
cells, indicating that APP internalization is required for increased
formation of intracellular Aβ in NPC cells. As expected, a substantial
decrease of secreted Aβ40 levels was also observed in both APPΔCT-
transfected CHOwt and NPC cells compared to APPwt-transfected
cells (Fig. 1A).
Since formation of Aβ depends on dual action of both β- and
γ-secretase and is prevented by α-secretase cleavage, we analyzed
sAPPβ/α levels in APPwt- and APPΔCT-transfected cells to validate
β-/α-secretase cleavage of APPΔCT construct vs. APPwt. In accor-
dance with the proposed spatial APP cleavage mechanism which as-
sumes that α-secretase cleavage of APP occurs at the cell surface
[10] while β-secretase cleavage is mainly localized within endocytic
compartments [7–9], we show completely diminished levels of
sAPPβ in APPΔCT-transfected cells, both CHOwt and NPC, while
sAPPα levels were increased compared to the levels in APPwt-
transfected cells (Fig. 1B). This result conﬁrmed that internalization
of the cell surface APP is required for increased processing of APP by
β-secretase upon NPC1 dysfunction.
3.2. Cholesterol accumulation in NPC cells traps APP within early/
recycling endocytic compartments
Next, we hypothesized that alteration in cholesterol metabolism
in NPC cells modulates endocytic trafﬁcking of APP and/or BACE1.
To determine the localization of APP in the endocytic pathway, we
used CHOwt and NPC cells stably transfected with HA-SEAP-APPwt
construct. These cells enabled us to analyze APP localization with dif-
ferent N-terminal and C-terminal anti-APP antibodies, together with
an anti-HA antibody, by immunocytochemistry and confocal micros-
copy. To conﬁrm that this tagged exogenous APP protein shows the
same trafﬁcking as the endogenous APP, we compared co-staining
of endogenous APP in non-transfected and HA-SEAP-APP stably
transfected CHOwt and NPC cells by anti-APP C-terminal antibody
(APP-CT) 6687 with two different endocytic markers: transferrin re-
ceptor (TfR) for recycling endosomes and bis (monoacylglycero)
phosphate (BMP) for late endosomes. HA-SEAP-APP showed the
same co-staining with endocytic markers as endogenous APP protein
indicating that its trafﬁcking in the cell is not altered by the tags or
transfection (supplement, Fig. S2A and B).
As shown in Fig. 2, immunostaining of APP (using either N-
terminal APP antibody 5313 or anti-HA) and protein markers for
early endosomes (EEA1), late endosomes (BMP), recycling endo-
somes (TfR) or lysosomes (LAMP1) revealed a strong vesicular stain-
ing of APP and colocalization with early endosome marker EEA1 and
recycling endosome marker TfR in NPC cells compared to CHOwt
(Fig. 2A and B). Weak or no colocalization of N-terminally stained
Fig. 1. APP internalization is required for increased processing of APP through the β-secretase pathway in NPC cells. CHOwt and NPC cells were transiently transfectedwith APPwt-6myc
and myc-APPΔCT constructs. A) Soluble (RIPA-extractable) and insoluble (FA-extractable) intracellular Aβ40, as well as secreted Aβ40 levels were detected by Aβ40 ELISA assay (Invi-
trogen). Shown are mean and SEM of three independent experiments. Statistical analysis was performed using Student's t-test: *pb0.05, **pb0.01, ***pb0.001. B) The levels of ﬂAPP
and sAPPα/sAPPβwere determined in the cell lysate and conditioned media, respectively, by western blotting using indicated antibodies.
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LAMP1) in both CHOwt and NPC cells (Fig. 2C and D). We further test-
ed whether APP protein is associated to either cholesterol- and/or
glyosphingolipid (GSL)-rich compartments within endocytic pathway
upon NPC1-loss. Free cholesterol accumulation was analyzed by ﬁli-
pin staining, while GSL-rich compartments were visualized by uptake
of a ﬂuorescent GSL analog, BODIPY-LacCer [38]. As expected and in
accordance with previous studies [25], we observed that in NPC
cells APP did not colocalize with ﬁlipin stained cholesterol-rich com-
partments (Fig. 2E) nor it colocalized with accumulated GSLs
(Fig. 2F). Because of the rapid cellular turnover of APP, we presume
that N-terminal APP antibody mostly stained sAPP fragments in the
lumen of the vesicles and to a lesser extent ﬂAPP, indicating that
β-secretase cleavage of APP could mainly occur in early/recycling
endosome compartments in NPC cells. These results show that
APP protein is sequestered and thus more available for BACE1 cleav-
age within early/recycling endocytic compartments in NPC cells and
is not directly associated with compartments that accumulate lipids
i.e. late endosomes/lysosomes.
Each endosome/lysosome marker analyzed, as well as APP, showed
enlarged vesicular staining in NPC cells vs. CHOwt, supporting that cho-
lesterol/lipid trafﬁcking defect upon NPC1-loss causes alterations with-
in endocytic pathway leading to enlarged vesicles that could not be
normally processed as in wt cells [38]. A defect in subcellular organelles
in NPC cells was also observed upon subcellular fractionation. All pro-
tein markers for cellular compartments analyzed (endoplasmic reticu-
lum (ER): BIP/GRP78, trans-Golgi network (TGN): TGN-46, early
endosomes (EE): EEA1, late endosomes (LE): Rab7, recycling endo-
somes (RE): TfR, lysosomes (Lys): LAMP1) showed distinct fraction-
ation in NPC cells compared to CHOwt (supplement, Fig. S3),
indicating that cholesterol accumulation upon NPC1-loss causes altered
vesicular transport within the cell that does not only includecompartments that are enriched with cholesterol and glycosphingoli-
pids, i.e. late endosomes and lysosomes. Indeed, we observed increased
expression of ER-marker BIP/GRP78, EE-marker EEA1 and Lys-marker
LAMP1 in NPC cells compared to CHOwt, while protein markers EEA1
(EE), Rab7 (LE) and TfR (RE) as well as TGN-46 (TGN) showed a slight
shift towards heavier subcellular fractions in NPC vs. CHOwt cells. The
observed changes upon subcellular fractionation of markers EEA1, TfR
and LAMP1 are in accordance with their altered vesicular staining
shown in Fig. 2.
3.3. APP C-terminal fragments accumulate in late endosomes in NPC cells
To differentiate between full-length APP (ﬂAPP) and the prod-
ucts of APP processing, N-terminal APP fragments (sAPP) and C-
terminal APP fragments (CTFs), we costained HA-SEAP-APP stably
transfected CHOwt and NPC cells with antibodies against APP C-
terminus (APP-CT) and APP N-terminus (APP-NT). While staining
of compartments with both antibodies could indicate the presence
of ﬂAPP, a selective detection with APP-CT or APP-NT might repre-
sent localization of CTFs or of sAPP fragments, respectively (supple-
ment, Fig. S4).
Since 5313 and anti-HA antibodies stain N-terminus of HA-SEAP-
APP, representing mostly sAPP fragments, we also tested whether
staining with C-terminal APP antibody would show similar defect in
APP trafﬁcking in NPC cells vs. CHOwt. Notice that opposed to domi-
nantly luminal vesicular N-terminal APP staining, C-terminal APP
antibody dominantly stained limiting vesicular membrane repre-
senting membrane bound CTFs, and probably to minor extent
ﬂAPP. Immunostaining of HA-SEAP-APP stably transfected cells
using C-terminal APP antibody 6687 conﬁrmed enlarged punctate
vesicular staining of APP and CTFs colocalized with early (EEA1)
as well as recycling (TfR-positive) endosome compartments in
Fig. 2. NPC cells sequester APP in early and recycling endosomes but not in cholesterol-rich late endosomes and lysosomes. A–F) Representative images of CHOwt and NPC
cells stably expressing HA-SEAP-APP protein stained with two different N-terminal antibodies (APP-NT): 5313 — anti-APP N-terminus (green) or anti-HA tag antibody (red)
and different endocytic markers: A) EEA1 for early endosomes, B) transferrin receptor (TfR) for recycling endosomes, C) bis(monoacylglycero)phosphate (BMP) for late endo-
somes and D) LAMP1 for lysosomes. Lipid-rich endocytic vesicles were also detected by: E) ﬁlipin staining which detects free cholesterol and F) Bodipy-LacCer uptake which is
ﬂuorescent glycosphingolipid (GSL) analog. Note that there is no colocalization of APP with cholesterol and GSL rich compartments.
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to N-terminally stained APP, C-terminal staining revealed partial
vesicular colocalization of CTFs with late endosome marker (BMP)
in NPC cells vs. CHOwt (Fig. 3C). This suggests that CTFs, formed
in upstream endocytic compartments, are shifted towards and accu-
mulate in cholesterol-rich late endosomes/lysosomes in NPC cells.
We additionally conﬁrmed our immunocytochemistry results,
which showed increased APP and CTFs compartmentalization within
early/late endosomes between CHOwt and NPC cells, by endosome
fractionation. We monitored endogenous ﬂAPP and CTFs levels in
each fraction by immunoprecipitation and western blotting. As
shown in Fig. 3D (upper panel), we separated early (EE, EEA1marker)
from late endosome (LE, Rab7 marker) fractions. By measuring total
cholesterol levels in each fraction (LE, EE and heavy fraction — HF)
we conﬁrmed increased cholesterol levels in late endosome vs. earlyendosome fraction in NPC cells compared to CHOwt (Fig. 3D, lower
panel). In accordance with the results of immunostaining using
C-terminal APP antibody (Fig. 3A–C), we detected a marked accumu-
lation of CTFs in late endosome fraction and to a lesser extent in early
endosome fraction in NPC cells vs. CHOwt (Fig. 3D, upper panel). As
Runz et al. [21] previously reported, we detected a slight shift of
presenilin 1 (PS1) towards late endosome fraction in NPC cells
compared to CHOwt (Fig. 3D, upper panel).
3.4. Cholesterol accumulation upon NPC1-loss causes increased
internalization and decreased recycling of APP
The observed increased localization of APP protein in early/
recycling endosome compartments in NPC vs. CHOwt cells may be
due to either its increased internalization, or due to its decreased
Fig. 3. APP C-terminal fragments accumulate in late endosomes in NPC cells. A–C) Representative images of CHOwt and NPC cells stably expressing HA-SEAP-APP protein
stained with 6687, an anti-APP C-terminal (APP-CT) antibody and different endocytic markers: A) EEA1 for early endosomes, B) transferrin receptor (TfR) for recycling endo-
somes and C) bis(monoacylglycero)phosphate (BMP) for late endosomes. D) Endosome fractionation in CHOwt and NPC cells. Protein levels were analyzed by western blot in
different fractions: early endosomes (EE), late endosomes (LE) and heavy fraction (HF). Upper panel: EE and LE fractions were detected with EEA1 and Rab7 antibodies, respec-
tively. FlAPP was analyzed with 22C11, CTFs were detected by immunoprecipitation and western blotting using 6687 antibody and presenilin1 (PS1) was detected with 2953
(anti-PS1-NTF) antibody. Lower panel: Total cholesterol levels were determined in EE, LE and HF fractions by AmplexRed cholesterol assay (Molecular probes, Invitrogen).
Shown are mean and SEM of three independent experiments. Statistical analysis was performed using Student's t-test: ***pb0.001.
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CHOwt and NPC cells by antibody uptake assay using N-terminal
anti-APP antibody which stains ﬂAPP at the cell surface (Fig. 4A,
left panel). After indicated time periods (1, 10 and 20 min), the
cells were ﬁxed and stained with EEA1 antibody. While in CHOwt
cells at 10 min of internalization few colocalized puncta of APP
and EEA1 marker were observed, in NPC cells internalization
seemed to be enhanced showing several APP and EEA1 costained
vesicular structures (Fig. 4A, left panel). At 20 min of internalization
the number of APP/EEA1-positive vesicles markedly increased in
NPC cells compared to CHOwt (Fig. 4A, left panel). Quantiﬁcation
of APP and EEA1-positive vesicles after 10 and 20 min uptake con-
ﬁrmed these observations (Fig. 4A, right panel). These results indi-
cate that previously observed decreased cell surface expression ofAPP in NPC cells [23] could be due to increased APP internalization
upon cholesterol accumulation in NPC cells.
It has been previously shown that cholesterol accumulation in
NPC cells causes decreased and inefﬁcient recycling of transferrin
and transferrin receptor [39]. To test whether accumulation of choles-
terol could also affect recycling of APP, we analyzed recycling of en-
dogenous N-terminally stained APP after 30 and 60 min between
CHOwt and NPC cells (Fig. 4B). While in CHOwt cells we could not ob-
serve any APP staining within the cell after 30 and 60 min of incuba-
tion, in NPC cells at these time points intracellular N-terminal APP
staining was still observed, indicating decreased and inefﬁcient recy-
cling of APP (Fig. 4B). This result, together with our previous ﬁnding
of increased APP colocalization with recycling endosome marker —
TfR in NPC cells vs. CHOwt, supports that cholesterol accumulation
Fig. 4. Cholesterol accumulation in NPC cells causes increased internalization and decreased recycling of APP. A) Representative images of APP uptake assay in CHOwt and NPC
cells stably expressing HA-SEAP-APP protein (left panel). After the uptake of the N-terminal APP antibody 5313 (green) in different time periods (1, 10 and 20 min) cells were
ﬁxed and stained with early endosome marker EEA1 (red). APP internalization was quantiﬁed in double blind conditions by counting the APP and EEA1 colocalized vesicles
(yellow) per cell (n=22) at different time points (right panel). Statistical analysis was performed using Student's t-test: *pb0.05, **pb0.01. B) Representative images of endog-
enous APP recycling assay in CHOwt and NPC cells. After 20 min of anti-APP N-terminal antibody 5313 internalization, cells were washed and allowed to recycle APP for the
indicated time periods (0, 30 and 60 min). Cells were then ﬁxed and stained with the secondary Alexa488 conjugated antibody. Note that there is a clear ﬂuorescence signal
accumulation in NPC cells compared to wt cells indicating a decreased recycling of APP in NPC cells.
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APP protein in enlarged punctate TfR-positive vesicles within endocy-
tic pathway.3.5. BACE1 resides in TfR-positive endosome compartments in NPC cells
Since our results indicate that APP protein is sequestered within
early/recycling endocytic compartments in NPC cells and thus more
available for BACE1 cleavage, we analyzed the localization of BACE1
upon cholesterol accumulation due to NPC1 loss-of-function in
BACE1-GFP stably expressing CHOwt and NPC cells. Staining of EEA1
(early endosome, Fig. 5A), TfR (recycling endosome, Fig. 5B) and
BMP (late endosome/lysosome, Fig. 5C) markers in BACE1-GFP stable
cells revealed strong vesicular localization of BACE1 in TfR-positive
compartments (Fig. 5B), similar to what was observed for APP
(Figs. 2B and 3B) in NPC cells. No colocalization of BACE1 with
BMP-positive compartments was detected in NPC cells (Fig. 5C), con-
ﬁrming that BACE1-generated CTFs that accumulate within late en-
dosome compartments in NPC cells (Fig. 3C and D) were likely not
generated within late endocytic vesicles but were rather shifted
from early/recycling to late endosomes/lysosomes. Endosome frac-
tionation conﬁrmed that no BACE1 was detected in late endosome
fraction (LE) and that majority was found in EEA1/TfR-positive frac-
tions (EE) both in CHOwt and NPC cells (Fig. 5D).3.6. NPC cells show colocalization of APP and BACE1 in enlarged vesicles
The observed sequestration of APP and BACE1 in TfR-positive
vesicles (“recycling” endosomes) in NPC cells vs. CHOwt suggested
that endocytic trafﬁc jam, due to cholesterol accumulation, may
trap APP and BACE1 within the same compartments resulting in in-
creased APP cleavage by β-secretase (BACE1) [23] and, thus, in-
creased APP-CTFs and Aβ levels as reported previously [19–23,25].
To test this we transiently transfected APP-RFP construct in BACE1-
GFP stable CHOwt and NPC cells. While in both CHOwt and NPC
cells we observed colocalization of APP and BACE1, in NPC cells the
co-staining revealed large punctate vesicular structures which were
positive for both APP and BACE1 (Fig. 6). This result suggests that
increased formation of the enzyme–substrate (BACE1–ﬂAPP) com-
plex within the endocytic compartments of NPC cells may be the
primary cause of increased processing of APP through the amyloido-
genic β-secretase pathway.
3.7. APP and BACE1 trafﬁcking defect in NPC cells is dependent on
cholesterol accumulation
Since we have recently shown that cholesterol depletion reverts
intracellular Aβ and APP-CTFs levels in NPC cells to that as in wt
cells [23], we therefore hypothesized that restoring normal levels of
cholesterol in NPC cells could correct trafﬁcking defect of APP and/
Fig. 5. BACE1 is sequestered in transferrin receptor positive endosome compartments in NPC cells. A–C) Representative images of CHOwt and NPC cells stably expressing BACE1-
GFP protein stained with different endocytic markers: A) EEA1 for early endosomes, B) transferrin receptor (TfR) for recycling endosomes and C) bis(monoacylglycero)phosphate
(BMP) for late endosomes. D) Endosome fractionation in BACE1-GFP stably transfected CHOwt and NPC cells. Protein levels were analyzed by western blot in different fractions:
early endosomes (EE), late endosomes (LE) and heavy fraction (HF). Early endosomes (EEA1), recycling endosomes (TfR) and late endosomes (Rab7) were detected with appro-
priate antibodies. BACE1-GFP in fractions was detected using anti-BACE1 antibody.
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colocalization of APP and EEA1 in both untreated CHOwt and un-
treated and cholesterol-depleted NPC cells (Fig. 7A). Cholesterol
was depleted by growing the cells in the media containing a lipid-
deﬁcient serum (LPDS) instead of FBS, by statin-treatment and by
treating cells with methyl-β-cyclodextrin (MβC) both acutely and
chronically. Filipin staining revealed that all treatments reduced cho-
lesterol accumulation in NPC cells (Fig. 7A). Interestingly, cholesterol
depletion in NPC cells restored APP trafﬁcking to that as in untreatedFig. 6. NPC cells show colocalization of APP and BACE1 in enlarged vesicles. Represen-
tative images of CHOwt and NPC cells stably expressing BACE1-GFP transiently trans-
fected with APP-RFP construct.CHOwt cells, statin- and MβC-treatments showing the strongest ef-
fect. Indeed, in cholesterol-depleted NPC cells we observed decreased
APP punctate staining similar to that as in untreated CHOwt cells
(Fig. 7B). Similar results were observed for BACE1 as well (Fig. 7C).
Cholesterol-depletion in NPC cells reversed BACE1-punctate vesicular
staining in NPC cells to a Golgi-like staining as in CHOwt cells
(Fig. 7C). These results demonstrate that APP and BACE1 trafﬁcking
defect in NPC cells is dependent on cholesterol accumulation.
To further conﬁrm this we tested whether cholesterol loading in
CHOwt cells would generate a similar defect in APP and BACE1 traf-
ﬁcking as in NPC cells. To load cholesterol we used two different
approaches: U18666A-treatment, the most widely used approach to
mimic NPC phenotype, and MβC-cholesterol treatment. Filipin stain-
ing of free cholesterol (Fig. 8A) conﬁrmed that U-treatment of CHOwt
cells generated intracellular cholesterol sequestration similar as in
NPC cells, while treatment with MβC-cholesterol complex caused in-
creased ﬁlipin staining of the whole cell (plasma membrane and
inner cell membranes), as expected. Quantitative analysis of choles-
terol levels using Amplex Red Cholesterol Assay (Invitrogen) con-
ﬁrmed that MβC-cholesterol complex treatment of CHOwt cells
caused an increase in free cholesterol levels similar to that as in NPC
cells (not shown). Interestingly, under these cholesterol loading con-
ditions in CHOwt cells (U- and MβC-cholesterol treatment) both APP
and BACE1 showed more punctuate vesicular staining in contrast to
their more perinuclear and Golgi-like staining in untreated wt cells,
respectively (Fig. 8B and C). Costaining with EEA1 (not shown) and
TfR showed increased punctuate colocalization of both APP and
BACE1 with TfR (Fig. 8B and C) similar as in NPC cells (Figs. 2 and
Fig. 7. APP and BACE1 trafﬁcking defect in NPC cells is dependent on cholesterol accumulation. A) Representative images of the N-terminal APP (APP-NT) and EEA1 co-staining
in CHOwt and NPC cells stably expressing HA-SEAP-APP protein. B) APP/EEA1 punctate staining (trafﬁcking defect) was quantiﬁed in double blind conditions by counting the
APP and EEA1 colocalized vesicles (yellow) per cell (n=20). Statistical analysis between NPC1−/− (FBS) condition and each cholesterol depletion treatment was performed
using Student's t-test: ***pb0.001. C) Representative images of CHOwt and NPC cells stably expressing BACE1-GFP. The cells were grown in 10% FBS DMEM/F12 media
(FBS) or different cholesterol depletion conditions: LPDS (10% lipoprotein deﬁcient serum DMEM/F12 for 48 h), statins (4 μM lovastatin and 0.25 mM mevalonate in 10%
LPDS DMEM/F12 for 48 h), acute MβC (10 mM methyl-β-cyclodextrin for 1 h after which the cells were kept in 10% LPDS DMEM/F12 for 24 h) and chronic MβC (1 mM
MβC in 10% LPDS DMEM/F12 for 24 h). The efﬁciency of cholesterol depletion was monitored by ﬁlipin staining in parallel samples.
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cholesterol loading in CHOwt cells was less profound compared to
their altered trafﬁcking in NPC cells, suggesting that cholesterol load-
ing may cause a milder alteration of endocytic trafﬁcking of APP andBACE1 compared to more harsh phenotype in NPC cells. Overall,
these results show that cholesterol loading caused by either NPC1-
depletion, U-treatment or MβC-cholesterol-treatment affects endo-
cytic trafﬁcking of APP and BACE1.
Fig. 8. Cholesterol loading affects endocytic trafﬁcking of APP and BACE1 even in non NPC1-deﬁcient environment. To load cholesterol we used two different approaches:
U-treatment (3 μg/ml U18666A for 48 h in 10% FBS media) and MβC-cholesterol treatment (100 μM MβC-cholesterol for 4 h in 10% LPDS media after 24 h of starvation in
10% LPDS media). A) Filipin staining of free cholesterol conﬁrmed that U18666A-treatment of CHOwt cells generated intracellular cholesterol sequestration similar as in NPC
cells, while treatment with MβC-cholesterol complex caused increased ﬁlipin staining of the whole cell (plasma membrane and inner cell membranes). B) Representative im-
ages of the N-terminal APP (APP-NT) and transferrin receptor (TfR) co-staining in untreated/treated-CHOwt and untreated-NPC cells stably expressing HA-SEAP-APP protein
and C) untreated/treated-CHOwt and untreated-NPC cells stably expressing BACE1-GFP costained with TfR. Costaining with TfR showed increased punctuate colocalization of
both APP and BACE1 similar as in NPC cells.
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sequestration within endocytic pathway
To further elucidate cholesterol-mediated APP trafﬁcking defect, we
treated primary rat hippocampal neurons with U18666A compound,
which mimics the NPC phenotype. Cholesterol accumulation was con-
ﬁrmed by ﬁlipin staining (Fig. 9A). We observed that upon U-treatment
APP/CTFs showed increased colocalization with TfR, a marker for
recycling endosomes (Fig. 9B). In addition, we observed to a lesser extent
colocalization with LAMP1, a marker for late endosomes/lysosomes
(Fig. 9C). These results further conﬁrm that upon cholesterol accumula-
tion APP/CTFs sequester within endocytic pathway, resembling pheno-
type observed in NPC cells.
4. Discussion
We have recently reported that CHO-NPC1−/− (NPC) cells show
cholesterol dependent increased processing of APP by β-secretase
and decreased expression of APP at the cell surface [23]. In this
study we further analyzed the mechanism behind this effect. Wedemonstrate that cholesterol accumulation in NPC1-deﬁcient cells al-
ters endocytic trafﬁcking of APP and BACE1 (β-secretase) causing
their sequestration within enlarged vesicular structures. Additionally,
we show that cholesterol-depletion corrects APP/BACE1 misstrafﬁck-
ing in NPC cells. Moreover, our cholesterol loading experiments
(using U18666A- and MβC-cholesterol-treatment) indicate that in-
creased cholesterol levels can alter APP and BACE1 trafﬁcking even
in non NPC1-deﬁcient environment. These results indicate that cho-
lesterol dependent trafﬁcking defect of APP and BACE1 in NPC cells
could lead to increased processing of APP by β-secretase generating
increased levels of APP-C-terminal fragments (CTFs) and intracellular
Aβ, the two central molecules in AD pathogenesis. Our ﬁndings sup-
port previous notion that altered endocytic trafﬁcking may be the pri-
mary defect in Alzheimer's disease [13–15] and that increased
cholesterol levels, such as in NPC disease and sporadic AD, may be
the upstream effector that drives these events.
Since increased cholesterol levels were found in AD brains [40–42]
and were shown to be a risk factor for sporadic AD [43,44] we sought
to employ an inherited disorder of cholesterol accumulation —
Niemann–Pick type C (NPC) — to further assess the mechanism(s) of
Fig. 9. U18666A-treated primary hippocampal neurons show APP/CTFs sequestration within endocytic pathway. Primary rat hippocampal neurons were cultured for 7 days and
subsequently treated with U18666A compound (1.5 μM for 48 h), to mimic the NPC phenotype. A) Filipin staining of free cholesterol conﬁrmed that U18666A-treatment gen-
erated intracellular cholesterol sequestration in the cell body of primary neurons. Representative images of primary hippocampal neurons stained with A8717, an anti-APP C-
terminal (APP-CT) antibody and different endocytic markers: B) transferrin receptor (TfR) for recycling endosomes and C) LAMP1 for late endosomes/lysosomes.
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lines of evidence supporting that cholesterol-dependent increased
endocytic sequestration of APP and BACE1 is responsible for increased
β-secretase processing of APP in NPC disease: 1) using APP-
internalization mutant (APPΔCT) we showed that APP endocytosis is
prerequisite for increased β-secretase processing of APP and increased
Aβ in NPC cells, 2) we showed that sequestration of both APP and
BACE1 within endocytic compartments in NPC cells leads to their
colocalization within enlarged vesicles, 3) we showed that accumu-
lation of APP within endocytic compartments in NPC cells is likely
due to both its increased internalization and decreased recycling to
the cell surface, 4), most importantly, we showed that cholesterol-
depletion corrects APP and BACE1misstrafﬁcking in NPC cells, 5) ad-
ditionally, we showed that increased cholesterol levels can alter APP
and BACE1 trafﬁcking in CHOwt cells even in non NPC1-deﬁcient
environment and 6) we also show that mimicking NPC phenotype
by U-treatment in primary rat hippocampal neurons alters APP
trafﬁcking within endocytic pathway.
Internalization of APP and/or BACE1 and their localization within
early endocytic compartments contributes to a major Aβ reservoir
of the cell [7,9,45]. However, Yamazaki et al. reported no effect of
APP internalization on increased Aβ levels in CHOwt cells treated
with U18666A, an inhibitor of NPC1 function that mimics NPC disease
[19]. To analyze whether observed increased intracellular levels of
APP-CTF/Aβ upon cholesterol accumulation in NPC1-deﬁcient (NPC)
cells are dependent on APP internalization, i.e. APP localization withinendocytic compartments, we used APP-internalization mutant
(APPΔCT) and compared its processing to APPwt-transfected CHOwt
and NPC cells. In contrast to Yamazaki et al. (2001), our ﬁndings
demonstrate that internalization of APP is prerequisite for increased
β-secretase processing of APP and increased Aβ levels in NPC cells,
conﬁrming that increased intracellular Aβ/CTFs upon cholesterol
accumulation in NPC cells are generated within endocytic pathway.
It was previously reported that endosome enlargement leads to
substantial increase in Aβ generation [13,16,46]. Our ﬁnding of APP
and BACE1 sequestration within enlarged endocytic compartments
in NPC cells (Fig. 6) further suggests that increased formation of
the enzyme–substrate (BACE1–ﬂAPP) complex within the endocytic
compartments may be the primary cause of increased Aβ and CTF
levels in NPC. Fig. 10 shows the summarized results on APP, BACE1
and PS1 trafﬁcking upon normal conditions and upon NPC1 dysfunc-
tion observed in this work and in previous studies [19–21,25]. Under
normal conditions there is more APP at the cell surface and less
within endocytic compartments resulting in less APP cleavage by
β- (BACE1) and γ-secretase in endosomes and less Aβ production.
Upon cholesterol accumulation in NPC disease APP is rapidly inter-
nalized and majority is sequestered within early/recycling enlarged
endosomes enabling increased amyloidogenic APP processing by
BACE1, which is also sequestered in TfR-positive vesicles. In parallel,
this results in markedly decreased expression of APP at the cell sur-
face and, thus, its decreased cleavage by non-amyloidogenic
α-secretase [23]. Cholesterol-accumulation upon NPC1 dysfunction
Fig. 10. Cholesterol-mediated sequestration of APP and BACE1 within endocytic compartments causes an Alzheimer's-like phenotype in NPC disease. The scheme shows the
summarized results of misstrafﬁcking of the three key proteins in AD pathogenesis (APP, BACE1 and PS1) upon NPC1 dysfunction, observed in this work and in previous studies
[19–21,25]. Under normal conditions there is more APP at the cell surface and less within endocytic compartments resulting in less APP cleavage by ¸β- (BACE1) and γ-secretase
in endosomes and less Aβ production. Upon NPC1 dysfunction, cholesterol accumulation causes increased APP internalization and decreased recycling to the cell surface result-
ing in its sequestration within endocytic compartments together with BACE1. This causes increased production and accumulation of both APP-CTFs and Aβ in cholesterol-rich
late endosome/lysosome compartments [19]. Intracellular accumulation of APP-CTFs and Aβ has been suggested to trigger pathological events leading to neurodegeneration and
Alzheimer's disease [54,55].
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The generated increased levels of APP-CTFs in early/recycling endo-
somes are shifted to late endosomes/lysosomes for their degradation
by PS1/γ-secretase complex to liberate Aβ [19]. While previous studies
mostly analyzed trafﬁcking of PS1 upon NPC1 dysfunction [20,21], we
detected, in accordance with Jin et al. [25], and Yamazaki et al. [19],
increased localization of the β-secretase APP-cleavage products, sAPP
and CTFs, in early/recycling endosome compartments and accumula-
tion of CTFs in late endosomes as well (Figs. 2 and 3). We did not
exclude that accumulation of APP-CTFs in cholesterol-rich late
endosomes/lysosomes in NPC cells is partly due to their decreased
degradation in these compartments. However, our previous ﬁnding
of no intracellular Aβ increase in CTFβ/C99-overexpressing NPC
cells [23] together with our results presented here support the notion
that increased intracellular Aβ/CTFs levels in NPC cells are primarily
due to their increased formation by enhanced β-secretase cleavage of
APP in early/recycling endosomes.
In addition to altered APP trafﬁcking, we showed that BACE1
(β-secretase) endocytic localization is grossly altered by cholesterol
accumulation in NPC cells showing its sequestration within enlarged
transferrin receptor positive endosomes at the cell periphery
(Fig. 5). BACE1 was not observed in BMP-positive late endosomes/
lysosomes suggesting that BACE1-generated APP-CTFs in early/
recycling compartments may either be cleaved by γ-secretase there
and/or may be shifted to late endosomes for degradation by γ-
secretase to release intracellular Aβ peptides (Fig. 10). In accordance
with this model, we observed accumulation of APP-CTFs in late endo-
some fraction (Fig. 3D) of NPC cells (CHO-NPC1−/−) while Yamazaki
et al. reported intracellular Aβ in late endosomes in NPC model cells
(U18666A-treated CHOwt) [19]. While previous study by Jin et al.
[25] suggested C-terminal APP accumulation within early endosomes
of Purkinje cells, we performed endosome fractionation to speciﬁcally
analyze APP-CTF distribution within early/late endosome fractions.
In contrast to Jin et al. [25] we found that in CHO NPC cells APP-
CTF accumulation is dominant in late endosomes but is found in
early endosomes as well. In summary, our ﬁndings suggest that
cholesterol-mediated defect in endosomal–lysosomal pathway gen-
erates increased sequestration of APP and BACE1 which causes in-
creased APP-CTF levels in NPC cells [23].
In this work we showed that sequestration of APP in early/
recycling endosomes in NPC cells may be due to increased APP inter-
nalization. This is in accordance with the recent ﬁnding showing thatelevated plasma membrane cholesterol levels cause increased
clathrin-mediated endocytosis of APP [18] and increased APP-BACE1
clustering [47]. Moreover, our cholesterol loading experiments
showed that both APP and BACE1 trafﬁcking is altered upon increased
cholesterol levels (Fig. 8). In addition, we also showed that recycling
of APP is substantially delayed in NPC cells. Pipalia et al. [39] have
previously reported delayed transferrin efﬂux in CHO NPC model
cells vs. CHOwt indicating a change in properties of the early/
recycling endosomal organelles and not just cholesterol rich late
endosomes/lysosomes [39]. Indeed, we observed enlarged punctate
EEA1-positive early endosomes, TfR-positive recycling and BMP-
positive late endosomes as well as LAMP1-positive lysosomes in
NPC cells vs. CHOwt, supporting that cholesterol accumulation in
late endosomes/lysosomes causes multiple defects within endocytic
pathway and endosomal sequestration of membrane proteins, such
as APP and BACE1, as well as their decreased expression at the cell
surface [23].
We have previously shown that cholesterol depletion in NPC cells
corrects β-amyloidogenic APP processing and reverts APP-CTF and Aβ
levels to the levels as in wt cells [23]. Finding that the same
cholesterol-depletion treatments correct APP and BACE1 trafﬁcking
in NPC cells to that as in CHOwt, further supports that increased amy-
loidogenic processing of APP in NPC cells is due to cholesterol-
mediated altered endocytic trafﬁcking of APP and BACE1. Since deple-
tion of the primary cholesterol accumulation in NPC disease in vitro
and in vivo models also causes secondary lipid alterations [48,49],
we cannot rule out that the observed trafﬁcking defect of APP and
BACE1 in NPC cells is not dependent nor speciﬁc to accumulated cho-
lesterol levels. Indeed, recent studies in NPC1−/− mice have shown
that chronic cyclodextrin treatment reduced neuronal primary cho-
lesterol and secondary glycosphingolipid (GM2 and GM3) storage
and, importantly, delayed the disease progression [49]. Additionally,
correction of the secondary lipid (sphingomyelin) accumulation by
restoring sphingomyelinase activity in NPC cells caused a dramatic
reduction in lysosomal cholesterol levels [50]. Moreover, it would
be interesting to analyze whether altered lipid catabolism in other
lipid storage disorders (LSDs), that were recently shown to accumu-
late APP-CTFs and Aβ as well [26,27], generates similar APP/BACE1
endocytic trafﬁcking defect as in NPC cells. These studies could
point to a unique mechanism of the lipid-effect on endosome dys-
function and AD pathogenesis. Besides the effect of altered lipid me-
tabolism on APP processing and Aβ formation, it has been recently
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sphingomyelin metabolism [51] as well as cholesterol efﬂux from
the brain [52]. Thus, the biological function of Aβ could be to act as
a feedback mechanism upon cholesterol-enhanced Aβ generation
within cells and mediate cholesterol depletion. Overall, these studies
suggest that there may be a bidirectional link between altered choles-
terol metabolism and Aβ function.
5. Conclusions
Endosome abnormalities were suggested as early changes lead-
ing to increased amyloidogenic APP processing and Aβ generation
in Alzheimer's disease and Down syndrome [14,53]. The observed
alterations of endocytic pathway in NPC disease, further support
that endosome dysfunction may be the initial event leading to in-
creased intracellular APP-CTFs and Aβ formation which have been
suggested to trigger pathological events leading to neurodegenera-
tion and Alzheimer's disease [54,55]. Our ﬁndings suggest that in-
creased cholesterol levels, such as in NPC disease and sporadic AD,
may be the upstream effector that drives amyloidogenic APP pro-
cessing characteristic for AD by altering endocytic trafﬁcking of
APP and BACE1. In future studies it would be important to identify
cholesterol-sensing effector(s) that drive these events as novel tar-
gets to develop therapies against Alzheimer's disease.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2012.04.002.
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